Arbutus Biopharma to present imdusiran, AB-101 data at The Liver Meeting 2025

Arbutus Biopharma (ABUS) announced that three abstracts featuring imdusiran data and one abstract featuring AB-101 data, have been accepted for poster presentations at the American Association for the Study of Liver Diseases – The Liver Meeting 2025, taking place November 7-11 in Washington, DC. Notably, the AB-101 abstract has been selected as a Poster of Distinction. Regular Abstracts Accepted as Poster Presentations: Presentation Title: Imdusiran is safe and well-tolerated after repeat dosing in chronic hepatitis B patients: An integrated safety analysis of Phase 1 and 2 imdusiran clinical trials: Key Findings: Imdusiran therapy in patients with chronic hepatitis B virus was safe and well tolerated when administered at both 60 mg and 90 mg dose levels every 8 weeks for 4 – 6 doses and through up to 48 weeks of follow up after imdusiran dosing. Presentation Title: IM-PROVE I: Hepatitis B virus genotype responsiveness to pegylated interferon alfa-2a may be enhanced with imdusiran combination treatment: Key Findings: In this limited dataset, the majority of subjects who achieved HBsAg response during pegylated interferon alfa-2a treatment with or following imdusiran dosing were genotype B or C. These findings contrast with historical data from IFN therapy and suggest that imdusiran may enhance IFN responsiveness in cHBV patients with specific HBV genotypes. Further studies in larger cohorts are warranted to confirm these observations. Presentation Title: Elevated soluble immune biomarkers in subjects with HBsAg loss after treatment with imdusiran and immunotherapeutic agents in the IM-PROVE I and IM-PROVE II studiesL Key Findings: Imdusiran treatment is associated with increases in soluble immune biomarkers in both IM-PROVE I and IM-PROVE II studies. In subjects who lost HBsAg and had anti-HBs antibodies, a greater breadth and magnitude of immune biomarker increases were observed in IM-PROVE I subjects compared to IM-PROVE II. In both studies, subjects who showed increases in soluble immune biomarkers on-treatment met nucleos(t)ide analogue therapy discontinuation criteria and had baseline HBsAg less than or equal to1000 IU/mL. Poster of Distinction: Presentation Title: Safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of AB-101, a small-molecule PD-L1 inhibitor, in chronic hepatitis B patients Key Findings: Oral doses of AB-101 up to 30 mg QD for 28 days were generally well tolerated in NA-suppressed cHBV patients. Preliminary interim pharmacodynamic data indicate dose-related increases in PD-L1 receptor occupancy, with 83% mean maximal receptor occupancy at the 30 mg dose. Cohort 3B is ongoing and all available data, including safety, PK, receptor occupancy and HBV biomarkers, will be presented.